{"entity":{"id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Partial Oncolysis in prostate cancer, run by Syncromune, Inc., now recruiting.","summary":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06533644 by Syncromune, Inc., with 91 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-04-14. Interventions recorded: Partial Oncolysis and SV-102.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06533644","url":"https://clinicaltrials.gov/study/NCT06533644"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06533644","phase":"2","setting":"A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Syncromune, Inc.","enrolled":91,"outcomes":[]},"route":"/trials/nct06533644/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}